Last $95.46 USD
Change Today +0.46 / 0.48%
Volume 563.7K
GEVA On Other Exchanges
As of 5:20 PM 12/19/14 All times are local (Market data is delayed by at least 15 minutes).

synageva biopharma corp (GEVA) Snapshot

Previous Close
Day High
Day Low
52 Week High
02/28/14 - $119.42
52 Week Low
09/22/14 - $60.19
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

Related News

No related news articles were found.

synageva biopharma corp (GEVA) Related Businessweek News

No Related Businessweek News Found

synageva biopharma corp (GEVA) Details

Synageva BioPharma Corp. operates as a biopharmaceutical company in the United States. It focuses on the discovery, development, and commercialization of therapeutic products for patients with rare diseases. The company’s lead program include sebelipase alfa, a recombinant form of human lysosomal acid lipase (LAL), which is under Phase III clinical trials for the treatment of LAL deficiency in infants, children, and adults. It also has various other research programs in various stages of preclinical development, including SBC-103, an enzyme replacement therapy for lysosomal storage diseases, known as mucopolysaccharidosis type IIIB, as well as protein therapeutic programs for rare life-threatening diseases. The company was founded in 1996 and is headquartered in Lexington, Massachusetts.

172 Employees
Last Reported Date: 03/4/14
Founded in 1996

synageva biopharma corp (GEVA) Top Compensated Officers

Chief Executive Officer, President, Secretary...
Total Annual Compensation: $601.1K
Chief Financial Officer and Senior Vice Presi...
Total Annual Compensation: $360.5K
Chief Medical Officer, Head of Research & Dev...
Total Annual Compensation: $380.1K
Executive Vice President of Medical and Regul...
Total Annual Compensation: $379.6K
Senior Vice President of Global Commercial Op...
Total Annual Compensation: $378.8K
Compensation as of Fiscal Year 2013.

synageva biopharma corp (GEVA) Key Developments

Synageva BioPharma Corp. Announces Active Investigational New Drug Application for SBC-103 for the Treatment of Mucopolysaccharidosis IIIB

Synageva BioPharma Corp. announced that the investigational new drug application to the U.S. Food & Drug Administration (FDA) to evaluate SBC-103 as a treatment for mucopolysaccharidosis IIIB (MPS IIIB, also known as Sanfilippo B syndrome) is active. The company plans to start enrolling patients with MPS IIIB in a Phase 1/2 study investigating intravenous administration of SBC-103 shortly and to report preliminary data from this study in 2015. SBC-103 is a recombinant form of the natural human alpha-N-acetyl-glucosaminidase (NAGLU) enzyme that has favorable properties for enabling cellular uptake and has shown the ability to overcome the challenges previously encountered in producing recombinant human NAGLU. The advancement of SBC-103 towards the clinic is supported by preclinical studies demonstrating that intravenously administered SBC-103 is able to cross the blood-brain barrier and reduce heparan sulfate (HS) storage in the brain and in the liver in an MPS IIIB animal model. In addition, SBC-103 demonstrated transport across an in vitro model of the blood-brain barrier and distributed into the brain in non-human primate studies. .

Synageva BioPharma Corp. Presents New Data from Phase 3 Study of Sebelipase Alfa in Children and Adults with LAL Deficiency at the AASLD Meeting

Synageva BioPharma Corp. announced that data from its Phase 3, global, double-blind, placebo-controlled trial evaluating sebelipase alfa in children and adults with lysosomal acid lipase deficiency (LAL Deficiency) were presented for the first time at a medical conference during the late-breaking session of The Liver Meeting(R), the 65(th) Annual Meeting of the American Association for the Study of Liver Diseases (AASLD). Positive top-line results from this trial were announced on June 30, 2014 and were a key focus of today's presentation. The new data presented at the AASLD meeting by a principal investigator described the magnitude of the impact of sebelipase alfa on a broad range of important disease-related abnormalities, and provided new insights into the severity of patients' liver disease and dyslipidemia at baseline. The investigator also presented data demonstrating sustained reductions in alanine aminotransferase (ALT, the study's primary endpoint and a marker of liver injury) and further improvements in LDL cholesterol at week 36 from the ongoing open-label extension period of the study. Trial design and baseline characteristics. The Phase 3 trial enrolled 66 children and adults with LAL Deficiency. Patients enrolled in the trial were randomized on a one-to-one basis to every other week infusions of sebelipase alfa (1 mg/kg) or placebo for the double-blind treatment period of 20 weeks. LAL Deficiency patients enrolled in the trial presented with multiple clinically important abnormalities at baseline. The median age of patients enrolled in the trial was 13 years of age (range 4-58) and fibrosis and/or cirrhosis was documented in 100% (32/32) of patients who had baseline biopsies. Data from the oral presentation further revealed that of the patients who had biopsies at baseline, 47% (15/32) had bridging fibrosis (defined as Ishak score 3 or 4) and an additional 31% (10/32) of patients had cirrhosis. Dyslipidemia was also common at baseline, with median LDL cholesterol levels of 204 mg/dL, which is in the very high category (greater than 190 mg/dL), and abnormally low median HDL cholesterol levels of 32.5 mg/dL, despite 39% (26/66) of patients already receiving lipid-lowering medications. Data from today's presentation also showed that 58% (38/66) of patients had LDL cholesterol levels at baseline in the very high category (greater than 190 mg/dL) despite 24% (9/38) of these patients receiving lipid-lowering medications. Impact on disease-related abnormalities. The trial met the primary endpoint with 31% (11/36) of sebelipase alfa patients reaching normalization of ALT (defined as 34-43 U/L, depending on age and gender) compared with 7% (2/30) of placebo patients (p=0.027). All sebelipase alfa patients showed a decrease in ALT with mean changes in ALT of -57.9 U/L and -6.7 U/L in the sebelipase alfa and placebo arms, respectively. In addition, treatment with sebelipase alfa showed significant improvements in multiple disease-related parameters of dyslipidemia and liver injury.

Synageva BioPharma Corp. Reports Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2014; Reiterates Earnings Guidance for the Year 2014

Synageva BioPharma Corp. reported consolidated earnings results for the third quarter and nine months ended September 30, 2014. For the quarter ended September 30, 2014, the company reported net loss of $48.3 million compared to a net loss of $28.1 million for the corresponding quarter of the prior year. Revenue was $1.326 million for the quarter ended September 30, 2014 consisted of Fuzeon royalties from Hoffman-La Roche Inc., compared to $1.369 million a year ago. Loss from operations was $48,038,000 compared to $28,196,000 a year ago. Loss before provision for income taxes was $48,303,000 compared to $28,123,000 a year ago. Net loss was $1.46 per diluted share, compared to $1.02 a year ago. For the nine months, the company's total revenue was $5,255,000 compared to $9,900,000 a year ago. Loss from operations was $134,827,000 compared to $64,959,000 a year ago. Loss before provision for income taxes was $134,933,000 compared to $64,714,000 a year ago. Net loss was $134,933,000 or $4.15 per diluted share, compared to $64,714,000 or $2.38 per diluted share a year ago. The company reiterates its previous net loss guidance of between $190 million and $205 million for 2014. The net loss is primarily due to investments supporting the global clinical development program for sebelipase alfa, development of SBC-103, expansion of the global clinical, medical affairs and commercial infrastructure, expansion of manufacturing capabilities, as well as advancement of other preclinical pipeline programs.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
GEVA:US $95.46 USD +0.46

GEVA Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for GEVA.
View Industry Companies

Industry Analysis


Industry Average

Valuation GEVA Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 365.0x
Price/Book -- Not Meaningful
Price/Cash Flow NM Not Meaningful
TEV/Sales -- Not Meaningful

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact SYNAGEVA BIOPHARMA CORP, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at